The oral vaccine developed by Kangtai Biological and its subsidiaries has started Phase III clinical trials
April 11, 2025
Source: drugdu
138
On April 9, Kangtai Biological (300601) issued an announcement, announcing that the oral pentavalent reassortant rotavirus attenuated live vaccine (Vero cells) developed by it and its wholly-owned subsidiary Minhai Biological has completed the preparations for Phase III clinical trials and successfully completed the first subject enrollment. This marks that the product development has made phased progress and further promoted the company's vaccine development process.
This Phase III clinical trial adopts a multi-center, randomized, double-blind, placebo-controlled design to evaluate the protective efficacy, safety and immunogenicity of the vaccine in Chinese infants and young children.
https://finance.eastmoney.com/a/202504093371486634.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bedaquiline Fumarate API Approved for Marketing, Enriching Anti-TB Drug Product Line July 25, 2025
- Huadong Medicine’s subsidiary’s Caspofungin Acetate for Injection approved by the U.S. FDA July 25, 2025
- Good news from AstraZeneca July 25, 2025
- A breakthrough in the cure of hepatitis B is in sight, and the share prices of leading pharmaceutical companies have doubled July 25, 2025
- A new hotspot in the innovative drug market July 25, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
